Skip to Main Content

Author Details

Ricky W Johnstone
The University of Melbourne
1990
259
80
PMIDPaper TitleJournal TitlePublished Year
37605534CRISPR-Cas9 screening identifies an IRF1-SOCS1-mediated negative feedback loop that limits CXCL9 expression and antitumor immunity.Cell Rep2023
37914685A<sub>2A</sub>R eGFP reporter mouse enables elucidation of A<sub>2A</sub>R expression dynamics during anti-tumor immune responses.Nat Commun2023
37643213Rationally designed chimeric PI3K-BET bromodomain inhibitors elicit curative responses in MYC-driven lymphoma.Proc Natl Acad Sci U S A2023
34782346BET Inhibition Enhances TNF-Mediated Antitumor Immunity.Cancer Immunol Res2022
35677155The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression.Front Oncol2022
35831623Epigenetic modulators of B cell fate identified through coupled phenotype-transcriptome analysis.Cell Death Differ2022
35514210Inhibition of pyrimidine biosynthesis targets protein translation in acute myeloid leukemia.EMBO Mol Med2022
35902886Distinct modulation of IFNγ-induced transcription by BET bromodomain and catalytic P300/CBP inhibition in breast cancer.Clin Epigenetics2022
35977494Inhibition of mutant IDH1 promotes cycling of acute myeloid leukemia stem cells.Cell Rep2022
36283704Stepwise progression of β-selection during T cell development involves histone deacetylation.Life Sci Alliance2022
35311997Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML.Cancer Discov2022
35061886SFPQ-ABL1 and BCR-ABL1 use different signaling networks to drive B-cell acute lymphoblastic leukemia.Blood Adv2022
34675395Targeting transcription cycles in cancer.Nat Rev Cancer2022
33259592Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas.Blood2021
33608275SUGAR-seq enables simultaneous detection of glycans, epitopes, and the transcriptome in single cells.Sci Adv2021
34475103A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer.Clin Cancer Res2021
33994371Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma.Clin Cancer Res2021
34019788Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition.Mol Cell2021
33990344CDK4/6 Inhibition Promotes Antitumor Immunity through the Induction of T-cell Memory.Cancer Discov2021
34004147The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer.Cell2021
34023423Regulatory T Cells Shape the Differential Impact of Radiation Dose-Fractionation Schedules on Host Innate and Adaptive Antitumor Immune Defenses.Int J Radiat Oncol Biol Phys2021
33436370Serine Biosynthesis Is a Metabolic Vulnerability in FLT3-ITD-Driven Acute Myeloid Leukemia.Cancer Discov2021
33375771Whole genome CRISPR screening identifies TOP2B as a potential target for IMiD sensitization in multiple myeloma.Haematologica2021
32152070Efficient CRISPR/Cas9 Gene Editing in Uncultured Naive Mouse T Cells for In Vivo Studies.J Immunol2020
31827241A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies.Leukemia2020
33086063Temporal Analysis of Brd4 Displacement in the Control of B Cell Survival, Proliferation, and Differentiation.Cell Rep2020
33208184Correction to: Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia.Clin Epigenetics2020
33035331MLL-TFE3: a novel and aggressive KMT2A fusion identified in infant leukemia.Blood Adv2020
32917631CDK13 cooperates with CDK12 to control global RNA polymerase II processivity.Sci Adv2020
32655143Distinct and overlapping mechanisms of resistance to azacytidine and guadecitabine in acute myeloid leukemia.Leukemia2020
32735774IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors.Mol Ther2020
32929243Targeting the epigenetic regulation of antitumour immunity.Nat Rev Drug Discov2020
32988967AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia.Clin Cancer Res2020
32120339Substituted 1-methyl-4-phenylpyrrolidin-2-ones - Fragment-based design of N-methylpyrrolidone-derived bromodomain inhibitors.Eur J Med Chem2020
30596220Rare T-Cell Subtypes.Cancer Treat Res2019
31727451Synthesis and elaboration of N-methylpyrrolidone as an acetamide fragment substitute in bromodomain inhibition.Bioorg Med Chem2019
31548725Joseph F. Sambrook (1939-2019).Nat Struct Mol Biol2019
31374198Interconversion between Tumorigenic and Differentiated States in Acute Myeloid Leukemia.Cell Stem Cell2019
31509742Natural Killer Cells Suppress T Cell-Associated Tumor Immune Evasion.Cell Rep2019
30902969Bcor loss perturbs myeloid differentiation and promotes leukaemogenesis.Nat Commun2019
30651288Antagonism of IAPs Enhances CAR T-cell Efficacy.Cancer Immunol Res2019
28914259Epigenetic targeting of Notch1-driven transcription using the HDACi panobinostat is a potential therapy against T-cell acute lymphoblastic leukemia.Leukemia2018
29907650JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias.Genes Dev2018
30069049Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth.Nature2018
29670108Down-regulation of a pro-apoptotic pathway regulated by PCAF/ADA3 in early stage gastric cancer.Cell Death Dis2018
29776993Tumor immune evasion arises through loss of TNF sensitivity.Sci Immunol2018
29322420A Comprehensive Protocol Resource for Performing Pooled shRNA and CRISPR Screens.Methods Mol Biol2018
27558082Durable clinical remission induced by romidepsin for chemotherapy-refractory peripheral T-cell lymphoma with central nervous system involvement.Leuk Lymphoma2017
28283481Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population.Blood2017
28280273A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML.Leukemia2017
  • 1 - 50 of 259

Recommended Authors

Zhengming Chen
Weill Cornell Medicine and New York Presbyterian Hospital
Career Start Year 2013
Number of shared co-authors 0
Amanda L Christie
Dana-Farber Cancer Institute
Career Start Year 2010
Number of shared co-authors 5
Huiyuan Zhang
Texas Children's Cancer Center
Career Start Year 2010
Number of shared co-authors 4
Anagha Deshpande
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2009
Number of shared co-authors 0
Jianying Zhang
City of Hope National Medical Center
Career Start Year 2009
Number of shared co-authors 0
Yang Chen
The University of Texas MD Anderson Cancer Center
Career Start Year 2008
Number of shared co-authors 1
Anupriya Agarwal
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2006
Number of shared co-authors 2
Anderly C Chueh
Biomedicine Discovery Institute, Monash University
Career Start Year 2005
Number of shared co-authors 2
Michele Ceribelli
National Center for Advancing Translational Sciences
Career Start Year 2004
Number of shared co-authors 2
Xiaohu Zhang
National Center for Advancing Translational Sciences
Career Start Year 2003
Number of shared co-authors 2
Aleksandra A Pandyra
Hematology and Clinical Immunology, Heinrich-Heine University Dusseldorf
Career Start Year 2003
Number of shared co-authors 0
Andrew V Kossenkov
The Wistar Institute
Career Start Year 2003
Number of shared co-authors 1
Rose Hurren
Princess Margaret Cancer Centre
Career Start Year 1999
Number of shared co-authors 1
Eric Tse
School of Clinical Medicine, University of Hong Kong
Career Start Year 1997
Number of shared co-authors 0
Changchun Deng
Center for Lymphoid Malignancies, Columbia University Medical Center
Career Start Year 1997
Number of shared co-authors 0
Timothy A Chan
Cleveland Clinic.
Career Start Year 1994
Number of shared co-authors 3
Ute Fischer
Hematology and Clinical Immunology, Heinrich Heine University Dusseldorf
Career Start Year 1992
Number of shared co-authors 0
Todd VanArsdale
Oncology Research Unit, Inc.
Career Start Year 1991
Number of shared co-authors 0
Linda Z Penn
University of Toronto
Career Start Year 1990
Number of shared co-authors 2
Aaron D Schimmer
Princess Margaret Cancer Centre
Career Start Year 1989
Number of shared co-authors 2
Todd R Golub
Broad Institute of MIT and Harvard
Career Start Year 1989
Number of shared co-authors 5
Lawrence H Boise
Winship Cancer Institute, Emory University
Career Start Year 1988
Number of shared co-authors 1
Wei Zhang
The University of Texas MD Anderson Cancer Center
Career Start Year 1988
Number of shared co-authors 1
Daniel E Johnson
University of California San Francisco
Career Start Year 1985
Number of shared co-authors 0
Marcela Gronda
Princess Margaret Cancer Centre
Career Start Year 1985
Number of shared co-authors 1
Louis M Staudt
National Cancer Institute, National Institutes of Health
Career Start Year 1983
Number of shared co-authors 7
Patrick Auberger
Universite Cote d'Azur, INSERM U5
Career Start Year 1982
Number of shared co-authors 0
Stephen E Kurtz
Knight Cancer Institute, Oregon Health and Science University
Career Start Year 1979
Number of shared co-authors 3
Scott H Kaufmann
Mayo Clinic
Career Start Year 1977
Number of shared co-authors 6
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Career Start Year 1976
Number of shared co-authors 10

Collaborators

Andrea Newbold
Peter MacCallum Cancer Centre
Co-authored papers 25
Grant A McArthur
University of Melbourne
Co-authored papers 18
Gareth P Gregory
School of Clinical Sciences at Monash Health, Monash University
Co-authored papers 15
Richard B Pearson
Co-authored papers 11
Peter Atadja
Co-authored papers 9
Paul G Ekert
Co-authored papers 8
Kaylene J Simpson
The University of Melbourne, Peter MacCallum Cancer Centre
Co-authored papers 7
Anthony T Papenfuss
Co-authored papers 7
Peter Leif Bergsagel
Co-authored papers 6
Karen E Sheppard
Co-authored papers 6
Richard B Lock
Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine
Co-authored papers 6
Daniel J Gough
Co-authored papers 6
Gordon K Smyth
The University of Melbourne
Co-authored papers 5
James E Bradner
Co-authored papers 5
Maria A Doyle
Peter MacCallum Cancer Centre
Co-authored papers 5
Leigh Ellis
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Co-authored papers 4
David D L Bowtell
Peter MacCallum Cancer Centre
Co-authored papers 4
Luciano G Martelotto
Monash University
Co-authored papers 4
Reinhard Kofler
Medical University of Innsbruck
Co-authored papers 3
Nathanael S Gray
Harvard Medical School
Co-authored papers 3
J Paul Secrist
Oncology R&D
Co-authored papers 3
Wendy Wei-Lynn Wong
Institute of Experimental Immunology, University of Zurich .
Co-authored papers 3
Louise E Ludlow
Co-authored papers 3
David E Levy
NYU Grossman School of Medicine
Co-authored papers 3
Victoria M Richon
Discovery and Preclinical Sciences
Co-authored papers 3
Michelle J Henderson
Children's Cancer Institute, Lowy Cancer Research Centre
Co-authored papers 2
Stephen Fawell
Oncology R&D
Co-authored papers 2
Justin Cidado
Oncology R&D
Co-authored papers 2
Richard A Scolyer
Co-authored papers 2
Kristin K Brown
Co-authored papers 2
Release 1.2